SNP information rs104886003

Research and publications:

  15016963   High frequency of mutations of the PIK3CA gene in human cancers.

  15254419   The PIK3CA gene is mutated with high frequency in human breast cancers.

  15520168   Mutation of the PIK3CA gene in ovarian and breast cancer.

  15608678   PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

  15647370   Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

  15805248   PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

  16906227   Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

  17673550   Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.

  18676830   An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

  18725974   Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

  19029981   Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

  19223544   PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

  19366826   PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

  19513541   A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.

  19903786   PIK3CA mutations predict local recurrences in rectal cancer patients.

  20619739   Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

  21430269   Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

  22162582   Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.

  22162589   Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

  22271473   PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

  22729223   De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.

  22729224   De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes.

  23408298   A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.

  23888070   PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.

  23946963   PIK3CA-Related Overgrowth Spectrum.

  25157968   Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

  26619011   Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.